Symptoms and Glycemic Control in Young People With Type 1 Diabetes Following SARS-CoV-2 Infection : An Observational Study
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
CONTEXT: Data is needed regarding the effect of SARS-CoV-19 infection on young people with established type 1 diabetes. Identifying the disease outcomes, short and long-term sequelae may help to establish an evidence-based prevention and education policy for sick days management and DKA prevention.
OBJECTIVE: This work aims to describe clinical manifestations of SARS-CoV-2 infection in children, adolescents, and young adults with established type 1 diabetes (T1D) and explore the effects of COVID-19 on glycemic control and disease course.
METHODS: An observational study was conducted at 3 pediatric diabetes clinics in Israel between mid-March 2020 and mid-March 2021. Included were young people with established T1D, age younger than 30 years, who tested positive for SARS-CoV-2 (quantitative real-time polymerase chain reaction). Data were collected from medical files, diabetes devices, and COVID-19 questionnaire. Outcome measures were analyzed by the presence/absence of clinical symptoms (symptomatic/asymptomatic) and by age group (pediatric, < 19 years/young adults, 19-30 years).
RESULTS: Of 132 patients, mean age 16.9 ± 5.3years, with COVID-19-confirmed infection, 103 (78%) had related symptoms; the most common were headaches, fatigue, fever, and loss of sense of smell. All had a mild disease course, but 4 required hospitalization and 2 cases were directly related to COVID-19 infection (pleuropneumonia in a patient with immunodeficiency syndrome, 1 case of diabetic ketoacidosis). Logistic regression analysis showed that age (odds ratio [OR] = 1.11; 95% CI, 1.01-1.23; P = .033), elevated glucose levels (OR = 5.23; 95% CI, 1.12-24.41; P = .035), and comorbidities (OR = 8.21; 95% CI, 1.00-67.51; P = .050) were positively associated with symptomatic infection. Persistent symptoms occurred in 16.5% of the cohort over a median of 6.7 months; age (OR = 1.14; 95% CI, 1.01-1.29; P = .030) and elevated glucose levels (OR = 3.42; 95% CI, 1.12-10.40; P = .031) were positively associated with persistent symptoms. Usually, no change was reported in glucose levels (64%) except for a temporary deterioration in glycemic control during the short infection period.
CONCLUSION: Young people with established T1D experience mild COVID-19 infection. Elevated glucose levels during COVID-19 infection and older age were associated with prolonged disease course.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:107 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 107(2022), 8 vom: 14. Juli, Seite e3264-e3272 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nimri, Revital [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Asymptomatic infection |
|---|
| Anmerkungen: |
Date Completed 18.07.2022 Date Revised 28.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1210/clinem/dgac288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340532262 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340532262 | ||
| 003 | DE-627 | ||
| 005 | 20231226005524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgac288 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340532262 | ||
| 035 | |a (NLM)35524727 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nimri, Revital |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Symptoms and Glycemic Control in Young People With Type 1 Diabetes Following SARS-CoV-2 Infection |b An Observational Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.07.2022 | ||
| 500 | |a Date Revised 28.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a CONTEXT: Data is needed regarding the effect of SARS-CoV-19 infection on young people with established type 1 diabetes. Identifying the disease outcomes, short and long-term sequelae may help to establish an evidence-based prevention and education policy for sick days management and DKA prevention | ||
| 520 | |a OBJECTIVE: This work aims to describe clinical manifestations of SARS-CoV-2 infection in children, adolescents, and young adults with established type 1 diabetes (T1D) and explore the effects of COVID-19 on glycemic control and disease course | ||
| 520 | |a METHODS: An observational study was conducted at 3 pediatric diabetes clinics in Israel between mid-March 2020 and mid-March 2021. Included were young people with established T1D, age younger than 30 years, who tested positive for SARS-CoV-2 (quantitative real-time polymerase chain reaction). Data were collected from medical files, diabetes devices, and COVID-19 questionnaire. Outcome measures were analyzed by the presence/absence of clinical symptoms (symptomatic/asymptomatic) and by age group (pediatric, < 19 years/young adults, 19-30 years) | ||
| 520 | |a RESULTS: Of 132 patients, mean age 16.9 ± 5.3years, with COVID-19-confirmed infection, 103 (78%) had related symptoms; the most common were headaches, fatigue, fever, and loss of sense of smell. All had a mild disease course, but 4 required hospitalization and 2 cases were directly related to COVID-19 infection (pleuropneumonia in a patient with immunodeficiency syndrome, 1 case of diabetic ketoacidosis). Logistic regression analysis showed that age (odds ratio [OR] = 1.11; 95% CI, 1.01-1.23; P = .033), elevated glucose levels (OR = 5.23; 95% CI, 1.12-24.41; P = .035), and comorbidities (OR = 8.21; 95% CI, 1.00-67.51; P = .050) were positively associated with symptomatic infection. Persistent symptoms occurred in 16.5% of the cohort over a median of 6.7 months; age (OR = 1.14; 95% CI, 1.01-1.29; P = .030) and elevated glucose levels (OR = 3.42; 95% CI, 1.12-10.40; P = .031) were positively associated with persistent symptoms. Usually, no change was reported in glucose levels (64%) except for a temporary deterioration in glycemic control during the short infection period | ||
| 520 | |a CONCLUSION: Young people with established T1D experience mild COVID-19 infection. Elevated glucose levels during COVID-19 infection and older age were associated with prolonged disease course | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a DKA | |
| 650 | 4 | |a SARS-CoV-2 infection | |
| 650 | 4 | |a asymptomatic infection | |
| 650 | 4 | |a pediatric | |
| 650 | 4 | |a type 1 diabetes | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Rachmiel, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Yackobovitch-Gavan, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Brener, Avivit |e verfasserin |4 aut | |
| 700 | 1 | |a de Vries, Liat |e verfasserin |4 aut | |
| 700 | 1 | |a Fisch Shvalb, Naama |e verfasserin |4 aut | |
| 700 | 1 | |a Lazar, Liora |e verfasserin |4 aut | |
| 700 | 1 | |a Oren, Asaf |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobi-Polishook, Talia |e verfasserin |4 aut | |
| 700 | 1 | |a Shefer Averbuch, Noa |e verfasserin |4 aut | |
| 700 | 1 | |a Tenenbaum, Ariel |e verfasserin |4 aut | |
| 700 | 1 | |a Mel, Eran |e verfasserin |4 aut | |
| 700 | 1 | |a Krepel Volsky, Sari |e verfasserin |4 aut | |
| 700 | 1 | |a Mouler, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Demol, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Shalitin, Shlomit |e verfasserin |4 aut | |
| 700 | 1 | |a Bello, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Phillip, Moshe |e verfasserin |4 aut | |
| 700 | 1 | |a Lebenthal, Yael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 107(2022), 8 vom: 14. Juli, Seite e3264-e3272 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:107 |g year:2022 |g number:8 |g day:14 |g month:07 |g pages:e3264-e3272 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgac288 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 107 |j 2022 |e 8 |b 14 |c 07 |h e3264-e3272 | ||